Literature DB >> 11859146

Airway hyperresponsiveness, late allergic response, and eosinophilia are reversed with mycobacterial antigens in ovalbumin-presensitized mice.

Michael T Hopfenspirger1, Devendra K Agrawal.   

Abstract

Pretreatment with mycobacterial Ags has been shown to be effective in preventing allergic airway inflammation from occurring in a mouse model. Because most asthmatics are treated after the development of asthma, it is crucial to determine whether mycobacterial Ags can reverse established allergic airway inflammation in the presensitized state. Our hypothesis, based upon our previous findings, is that mycobacteria treatment in presensitized mice will suppress the allergic airway inflammation with associated clinical correlates of established asthma, with the noted exception of factors associated with the early allergic response (EAR). BALB/c mice sensitized and challenged with OVA were evaluated for pulmonary functions during both the EAR and late allergic response, and airway hyperresponsiveness to methacholine. Following this, sensitized mice were randomized and treated with placebo or a single dose (1 x 10(5) CFUs) of bacillus Calmette-Guérin (BCG) or Mycobacterium vaccae via nasal or peritoneal injection. One week later, the mice were rechallenged with OVA and methacholine, followed by bronchoalveolar lavage (BAL) and tissue collection. Mice treated with intranasal BCG were most significantly protected from the late allergic response (p < 0.02), airway hypersensitivity (p < 0.001) and hyperreactivity (p < 0.05) to methacholine, BAL (p < 0.05) and peribronchial (p < 0.01) eosinophilia, and BAL fluid IL-5 levels (p < 0.01) as compared with vehicle-treated, sensitized controls. Intranasal M. vaccae treatment was less effective, suppressing airway hypersensitivity (p < 0.01) and BAL eosinophilia (p < 0.05). No changes were observed in the EAR, BAL fluid IL-4 levels, or serum total and Ag-specific IgE. These data suggest that mycobacterial Ags (BCG>>M. vaccae) are effective in attenuating allergic airway inflammation and associated changes in pulmonary functions in an allergen-presensitized state.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11859146     DOI: 10.4049/jimmunol.168.5.2516

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

Review 1.  The future of asthma therapy: integrating clinical and experimental studies.

Authors:  David B Corry; Farrah Kheradmand
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

2.  Attenuated Salmonella typhimurium reduces ovalbumin-induced airway inflammation and T-helper type 2 responses in mice.

Authors:  C-J Wu; L-C Chen; M-L Kuo
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

3.  The antiasthma effect of neonatal BCG vaccination does not depend on the Th17/Th1 but IL-17/IFN-γ balance in a BALB/c mouse asthma model.

Authors:  Yu Deng; Weichao Chen; Na Zang; Siming Li; Yan Luo; Ke Ni; Lijia Wang; Xiaohong Xie; Wei Liu; Xiqiang Yang; Zhou Fu; Enmei Liu
Journal:  J Clin Immunol       Date:  2011-02-22       Impact factor: 8.317

4.  Inhalation of stable dust extract prevents allergen induced airway inflammation and hyperresponsiveness.

Authors:  M Peters; M Kauth; J Schwarze; C Körner-Rettberg; J Riedler; D Nowak; C Braun-Fahrländer; E von Mutius; A Bufe; O Holst
Journal:  Thorax       Date:  2005-10-21       Impact factor: 9.139

5.  Cultured lung fibroblasts from ovalbumin-challenged "asthmatic" mice differ functionally from normal.

Authors:  Hisatoshi Sugiura; Xiangde Liu; Fenghai Duan; Shin Kawasaki; Shinsaku Togo; Koichiro Kamio; Xing Qi Wang; Lijun Mao; Youngsoo Ahn; Ronald F Ertl; Tom W Bargar; Abdo Berro; Thomas B Casale; Stephen I Rennard
Journal:  Am J Respir Cell Mol Biol       Date:  2007-06-15       Impact factor: 6.914

6.  Preventive effects of mycobacteria and their culture supernatants against asthma development in BALB/c mice.

Authors:  Eui-Ryoung Han; Inseon S Choi; Sun-Ho Eom; Hwa-Jung Kim
Journal:  Allergy Asthma Immunol Res       Date:  2009-12-30       Impact factor: 5.764

Review 7.  Health impacts of environmental mycobacteria.

Authors:  Todd P Primm; Christie A Lucero; Joseph O Falkinham
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

8.  Inhibition of airway allergic disease by co-administration of flagellin with allergen.

Authors:  Shee Eun Lee; Youngil I Koh; Mi-Kwang Kim; Young Ran Kim; Soo Young Kim; Jong Hee Nam; Yoo Duk Choi; Soo Jang Bae; Young Jong Ko; Hwa-Ja Ryu; Jeong Tae Koh; Hyon E Choy; Joon Haeng Rhee
Journal:  J Clin Immunol       Date:  2007-11-17       Impact factor: 8.317

Review 9.  Innate immune mechanism in allergic asthma.

Authors:  Carlos J Suarez; Nathan J Parker; Patricia W Finn
Journal:  Curr Allergy Asthma Rep       Date:  2008-09       Impact factor: 4.806

10.  Ag85B DNA vaccine suppresses airway inflammation in a murine model of asthma.

Authors:  Jian Wu; Jun Xu; Chuang Cai; Xinglin Gao; Li Li; Nanshan Zhong
Journal:  Respir Res       Date:  2009-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.